The core deal is unchanged and was already known. Vertex’s $85-per-share acquisition was announced July 6, and the shareholder meeting was already scheduled for August 28. 〔0〕 The new filing is a proxy supplement responding to three shareholder lawsuits and several demand letters, not a revised offer or a new strategic event.
The added valuation detail broadly supports, but does not clearly improve, the $85 price. J.P. Morgan’s public-company comparison produced a very wide implied range of $30.75 to $95.00 per share, while its selected-transaction analysis produced $47.75 to $84.75. Its discounted-cash-flow range was $68.25 to $86.00, putting the merger consideration near the top of that range rather than materially below it. The filing also discloses management’s risk-adjusted 2030 revenue forecast of $1.057 billion and approximately $1.209 billion of net cash (J.P. Morgan opinion and Management Forecasts sections).
| Valuation reference | Implied value or disclosed amount |
|---|---|
| Merger consideration | $85.00 per share (J.P. Morgan opinion disclosures) |
| J.P. Morgan public trading multiples | $30.75–$95.00 per share (J.P. Morgan opinion — Public Trading Multiples) |
| J.P. Morgan selected transactions | $47.75–$84.75 per share (J.P. Morgan opinion — Selected Transactions Analysis) |
| J.P. Morgan discounted cash flow | $68.25–$86.00 per share (J.P. Morgan opinion — Discounted Cash Flow Analysis) |
| 2030 risk-adjusted revenue forecast | $1,057 million (Management Forecasts) |
| Estimated net cash | Approximately $1,209 million (J.P. Morgan opinion — Discounted Cash Flow Analysis) |
The litigation adds process friction, not a changed economic outcome. The complaints seek additional disclosures, an injunction against closing unless disclosures are added, or damages, but Crinetics denies the allegations and continues to recommend approval. 〔1〕 The practical read is modestly more execution scrutiny ahead of the vote, without evidence in this filing that the transaction price or closing timetable has deteriorated.
The supplement increases visibility into banker incentives and negotiations. J.P. Morgan’s estimated fee is approximately $69.4 million, with most payable only if the merger closes, while Leerink Partners’ fee is approximately $60.8 million; those disclosures are relevant to shareholder review but do not change the recommendation or consideration. Net: this is a largely anticipated transaction confirmation with more disclosure and legal noise, so the filing reads neutral rather than as a new positive or negative repricing event.
Read the original 8-K on SEC EDGAR ↗